Godrej Agrovet Limited held a post-Q2 FY27 earnings conference call with investors and analysts on Friday, November 6, 2026, at 4:00 PM IST. The call was hosted by ICICI Securities Limited. The stated purpose was to discuss the company's financial and operational performance for the second quarter and first half of FY27, provide a strategic outlook, and address questions from analysts.

The call was scheduled after the earnings announcement. The management participants included:

  • Mr. Burjis Godrej – Chairperson
  • Mr. Sunil Kataria – Chief Executive Officer and Managing Director
  • Mr. Ravishankar A. – Chief Financial Officer
  • Mr. Arijit Mukherjee – Chief Operating Officer, Astec LifeSciences

The moderator was Mr. Probal Sen from ICICI Securities Limited.

The company provided a transcript of the conference call as a regulatory filing in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript was made available on the company's website at www.godrejagrovet.com. The disclosure included a compliance statement through its submission to the exchanges, confirming it was a record of past discussions.

Financial Highlights Discussed:

  • Q2 FY27 Consolidated Revenue: Grew 17% year-on-year to ₹2,995 crores.
  • Q2 FY27 EBITDA: Remained stable at ₹222 crores, with a margin of 7.4%.
  • Q2 FY27 Profit Before Tax (PBT): Grew 5% to ₹131 crores.
  • Q2 FY27 Profit After Tax (PAT): Grew 22% to ₹103 crores.
  • H1 FY27 Consolidated Revenue: Grew 13% to ₹5,847 crores.
  • H1 FY27 PAT: Stood at ₹231 crores.
  • Net Working Capital: Improved to 21 days from 32 days last year; absolute working capital reduced to ₹655 crores.

Segment-wise Performance:

  • Animal Nutrition: Revenue growth of 14%; segment profit growth of 32%. Exited shrimp feed business.
  • Oil Palm: Revenue growth of 28%; Fresh Fruit Bunch (FFB) volume growth of 14%; segment profit increased 4%. Added 13,000 hectares of plantations in H1. Commissioned a new mill, CPKO refinery, and biogas plant at the integrated Khammam complex.
  • Crop Care: Revenue grew on a lower base, but profitability declined due to El Niño-led demand weakness.
  • Astec LifeSciences: Weak enterprise demand offset CDMO growth; EBITDA impacted by lower realizations and input costs.
  • Dairy: Revenue grew 6%; value-added products now account for 49% of portfolio; profitability affected by high procurement and logistics costs.
  • Godrej Foods: B2C segment grew 50%; salience increased to 38% of the portfolio.
  • Bangladesh JV (ACI Godrej Agrovet): Delivered strong growth in volume, revenue, and profit.

Forward-Looking Statements & Strategic Themes:

  • Management acknowledged challenges from El Niño (monsoon 13% below normal), geopolitical volatility, and inflation.
  • Expressed confidence in navigating near-term challenges due to a strong market position, diversified portfolio, and healthy balance sheet.
  • Discussed a multi-year crop diversification strategy in Crop Care to reduce dependence on cotton and chili. New products launched include maize herbicide Ashitaka® (expected to cross ₹100 crores in first year), insecticide Takai®, and soybean herbicide Ghassnash®.
  • For Astec, the focus is on scaling the CDMO business to 50-55% of revenue; reported a 90% conversion rate from inquiries to R&D and a pipeline of 15 products.
  • In Oil Palm, the new PKO derivatives plant was commissioned on September 1, 2026; full commercial impact is expected from Q4 FY27 onwards, with a mid-term target to add ~2% to segment EBITDA margin.
  • For Godrej Foods, the strategy is to build a B2C, protein-forward company; expanding into frozen chicken, momos (veg and non-veg), and new nugget variants.
  • The company is piloting a new distribution model (AM/PM) for its dairy business in Chennai.

Management explicitly stated that the meeting was for discussion purposes and that no unpublished price sensitive information (UPSI) was shared.

Additional Notes Section

The regulatory filing was an intimation letter to the BSE and NSE, enclosing the full transcript of the conference call. The transcript itself was attached to the filing and formed the basis of this summary. The document is a verbatim record of the question-and-answer session, providing detailed management commentary.

No standalone financial statements or data sheets were included in this specific disclosure; all figures discussed were based on the earnings already announced. The dial-in numbers and access codes for the live call were not included in the transcript, as it is a post-event record.